A Study of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Soft Tissue Sarcomas

Inclusion Criteria:

* Must be 18 years of age or older with histologic diagnosis of soft tissue sarcoma
* Must have disease not suitable for curative resection
* Must have failed \>1 first line treatment with evidence of progression. Adjuvant therapy does not count as 1st line therapy unless recurrence occurs within 6 months of administration
* Must have ability to understand and the willingness to sign a written informed consent document
* Must have Eastern Cooperative Oncology Group (ECOG) performance status of \< 2
* Must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria
* At least 4 weeks have passed since the last chemotherapy, immunotherapy, or radiation therapy
* There must be measurable disease outside the radiotherapy fields or progression of the indicator lesions within the field since the completion of the radiotherapy
* Must have a life expectancy of greater than 12 weeks
* Must have clinical laboratory values at screening as defined below:
* Hemoglobin \>9 g/dL,
* Absolute neutrophil count \>1500/mm3,
* Platelet count \>100,000/mm3,
* Creatinine \<1.5 X ULN,
* Bilirubin \<1.5 X ULN,
* Asparate aminotransferase and alanine aminotransferase \<2.5 X ULN (\<5 X ULN in presence of liver metastases)

Exclusion Criteria:

* Female patients who are pregnant or breast feeding
* Patients of childbearing potential not using or not willing to use a barrier method of contraception
* Prior malignancy other than soft tissue sarcoma (STS) within the last 5 yrs with the exception of:

  * Adequately treated in situ carcinoma of the cervix uteri;
  * Basal or squamous cell carcinoma of the skin
* Presence of a clinically significant and uncontrolled infection
* Presence of \>Grade 2 neuropathy
* Symptomatic central nervous system metastases within last 8 weeks or on corticosteroids for CNS symptom management
* Presence of clinically significant arrythmias
* Presence of a serious concurrent illness or other conditions (e.g., psychological, family, sociological, or geographical circumstances) that do not permit adequate follow-up and compliance with the protocol
* History of severe hypersensitivity reactions to taxanes or cremaphore in spite of premedication
* Use of any investigational agents within 4 weeks prior to the first dose of study drug(s)
* Major surgery within 2 weeks of screening
* Radiation treatment in past \>25% of bone marrow